Company intelligence / Profile preview

HopeLink

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

HopeLink is a clinical-stage biotechnology company focused on the discovery and development of next-generation antibody-drug conjugates (ADCs) for the treatment of cancer. The company utilizes a proprietary platform that incorporates site-specific conjugation technologies and novel linkers to enhance the stability and therapeutic index of its candidates. Its lead program, HLK-001, is a HER2-targeted ADC currently undergoing clinical evaluation in patients with advanced solid tumors. HopeLink aims to address unmet medical needs in oncology by developing highly potent and selective therapies with improved safety profiles compared to traditional cytotoxic agents.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on HopeLink.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HopeLink.

Explore the full profile